BRCA1 and gastric cancer: Given the emerging risk of GC in germline BRCA1/2 PV carriers, future studies and clinical trials are crucial to more clearly determine the chemotherapeutic agents that are the most efficacious in the treatment of GC when BRCA1/2 expression is altered and/or in the presence of germline BRCA1/2 PVs.